FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
TUCSON, Ariz., Jan. 27, 2016 -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that its management will be presenting at the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016 in New York.
HTG management is scheduled to present at 8:25 a.m. ET. A live audio webcast of the presentation can be accessed by visiting the “Investors” section of HTG’s website at: http://www.htgmolecular.com. The webcast will be available on HTG's website for 90 days following the completion of the presentation.
About HTG Molecular Diagnostics:
Headquartered in Tucson, Arizona, HTG’s mission is to empower precision medicine at the local level. In 2013 the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG's proprietary nuclease protection chemistry. HTG’s product offerings have since expanded to include its HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing. Additional information is available at www.htgmolecular.com.
Contact: Westwicke Partners Jamar Ismail Phone: 415-513-1282 Email: [email protected] TJ Johnson President / CEO HTG Molecular Diagnostics Phone: 520-547-2827 x130 Email: [email protected]
